title: Is Open Science the Future of Drug Development?
abstract: Traditional drug development models are widely perceived as opaque and inefficient, with the cost of research and development continuing to rise even as production of new drugs stays constant. Searching for strategies to improve the drug discovery process, the biomedical research field has begun to embrace open strategies. The resulting changes are starting to reshape the industry. Open science-an umbrella term for diverse strategies that seek external input and public engagement-has become an essential tool with researchers, who are increasingly turning to collaboration, crowdsourcing, data sharing, and open sourcing to tackle some of the most pressing problems in medicine. Notable examples of such open drug development include initiatives formed around malaria and tropical disease. Open practices have found their way into the drug discovery process, from target identification and compound screening to clinical trials. This perspective argues that while open science poses some risks-which include the management of collaboration and the protection of proprietary data-these strategies are, in many cases, the more efficient and ethical way to conduct biomedical research.
authors.affiliation: Yale School of Medicine, Yale University, New Haven, CT.
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Shaw
mesh_terms: D035843:Biomedical Research; D055808:Drug Discovery; D004345:Drug Industry / Q000706:statistics & numerical data
keywords: Crowdsourcing; Drug Discovery; Drug Industry; Open Science; Pharmaceutical Research; Reproducibility of Results; Research Design; Research Ethics